Coya Therapeutics (COYA) vs Fortress Biotech (FBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fortress Biotech (FBIO) has outperformed Coya Therapeutics (COYA) over the past year, losing 26.6% versus a loss of 50.7%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $64.1 million), about 1.1 times the size. Fortress Biotech converts more of its revenue into profit, with a net margin of 10.8% versus -267.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | FBIO |
|---|---|---|
| Share price | $2.95 | $1.90 |
| Market cap | $69.20M | $64.11M |
| 1-day change | -1.01% | +7.34% |
| YTD return | -49.14% | -48.09% |
| 1-year return | -50.67% | -26.64% |
| 5-year return | — | -95.52% |
| P/E ratio (TTM) | — | 0.83 |
| EPS (TTM) | $-1.39 | $2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.95M | $63.26M |
| Revenue growth (YoY) | +123.57% | +9.69% |
| Net income (latest FY) | $-21.23M | $6.82M |
| Gross margin | — | 66.92% |
| Operating margin | -283.87% | -111.00% |
| Net margin | -267.14% | 10.77% |
| 52-week high | $6.62 | $4.53 |
| 52-week low | $2.72 | $1.64 |
| Distance from 52-week high | -55.44% | -58.06% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +415.59% | +163.16% |
| Average volume | 149.18K | 281.49K |
| Shares outstanding | 23.46M | 33.74M |
| Employees | 8 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed COYA by 24.0 percentage points over the past year.
- Fortress Biotech is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -267.1 cents for Coya Therapeutics.
- Coya Therapeutics grew revenue faster in its latest fiscal year (+123.57% vs +9.69%).
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
COYA vs FBIO FAQ
Which is bigger, Coya Therapeutics or Fortress Biotech?
Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $64.11M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, COYA or FBIO?
FBIO returned -26.64% over the past 12 months, compared with -50.67% for COYA (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Fortress Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.